Follow the Pundits

Tag: Biotech Innovation

Illustration of a roller coaster shaped like a stock chart labeled “ARKK,” with symbols of AI, biotech, Tesla, and crypto, representing the volatility and comeback of Cathie Wood’s innovation fund.

ARKK 2025: The “Mojo” Is Back (But the Volatility Never Left)

ARKK crushed 2025, face-planted in early 2026, and reminded everyone why Cathie Wood’s fund is the wildest ride in innovation investing. Fun, data-driven, and brutally honest about the volatility.

Read entire article

Tags: #FoodieInParis, AI Investing, AMD, Ark Invest, ARKK, ARKK Fund, ARKK stocks, Biotech, Biotech Innovation, Biotech Investing, Biotech Investments, Biotech Picks, Biotech Stocks, BiotechGrowth, BiotechInvesting, Biotechnology Innovation, Cathie Wood, Cathie Wood Stocks, Coinbase, CRISPR Therapeutics, CRSP, Crypto Stocks, featured-hedge-funds, FUNanc1al, FUNanc1al Edge, FUNanc1al Investing, Funds, Growth Investing, hub-hedge, Innovation ETFs, Portfolio Strategy, Robinhood, Roku, SHOP, Shopify, Tech Stocks, TEM, Tempus AI, Tesla, TSLA, Volatility
Modern editorial illustration of CRISPR gene editing: a DNA helix morphs into a stock chart, with lab and Wall Street symbols representing breakthrough biotech potential and high volatility risk.

Revisiting The Case of CRISPR Therapeutics: Still Crisp, Still Risky, Still Dangerously Alluring

CRISPR Therapeutics (CRSP) has the first widely approved CRISPR-based therapy, huge insider buying near today’s price, and institutions (including ARK) deep in the name — while shorts pile on. Crisp setup, risky execution, dangerously alluring upside. 🧬🎯

Read entire article

Tags: ARKG, ARKK, ARKK Fund, ARKK stocks, Biotech, Biotech Humor, Biotech Innovation, Biotech Investing, biotech jokes, Biotech Picks, Buy or sell CRSP, CASGEVY, Cathie Wood, Cathie Wood Stocks, CRISPR Therapeutics, CRSP, featured-hedge-funds, funanc1al edge, funanc1al humor, funanc1al investing, FUNstock Index, Gene Editing, Growth Stocks, High Risk High Reward, hub-hedge, hub-insiders, Insider Purchases, risks buying crsp, Short Interest, why buy crsp
Cartoon of hedge fund managers conducting a biotech orchestra, with Madrigal Pharmaceuticals (MDGL) rocket blasting off.

Biotech Hedge Fund Extraordinaire Baker Bros. Advisors LP Adds To Its Stake in Madrigal Pharmaceuticals (MDGL): Should You Buy?

When the Baker Bros. — biotech’s most famous hedge fund — start scooping up more shares of Madrigal Pharma (MDGL), you know something’s cooking. With Rezdiffra sales booming, losses shrinking, and Wall Street titans circling, the tune of this Madrigal might be worth humming 🎶.

Read entire article

Tags: BakerBros, Biotech, Biotech Humor, Biotech Innovation, Biotech Investing, Biotech Investments, Biotech Stocks, BiotechGrowth, BiotechHumor, BiotechInvesting, Biotechnology, Biotechnology Innovation, BiotechStocks, Funanc1alBiotech, Growth in Biotech, GrowthStocks, HedgeFunds, Investing, MDGL, MDGL Stock, NASH, Pharmaceuticals, StocksToWatch, WallStreet